Integrated Diagnostics Holdings PLC Launch of data-driven healthcare support (7365L)

TIDMIDHC

RNS Number : 7365L

Integrated Diagnostics Holdings PLC

10 September 2019

IDH launches new subsidiary "Wayak" to offer data-driven healthcare support

The new venture will utilise data analytics to capitalise on IDH's vast database of over c.13 million patients and offer targeted healthcare services

10 Sep 2019

(Cairo and London) - Integrated Diagnostics Holdings ("IDH," "the Group," or "the Company"), IDHC on the London Stock Exchange, a leading consumer healthcare company with operations in Egypt, Jordan, Sudan and Nigeria, announces the launch of its new Egypt-based subsidiary "Wayak" to invest in data mining and artificial intelligence platforms. Wayak will leverage the Group's patient database to capture new growth opportunities in the healthcare management space and offer targeted services to its customers.

With a database covering more than 13 million patients, of which c.10% suffer from chronic diseases, Wayak will allow IDH to build electronic medical records of patients and better cater to their needs with new value propositions. These include building patient healthcare profiles, home-delivery of medications, diagnostics testing reminders, referrals to service providers under IDH's network with discounted prices as well as follow-up services, amongst others.

Wayak is a joint venture that is 94% owned by IDH and 6% owned by renowned data analytics scientist and angel investor Dr. Khaled Ismail through his angel investment fund HIMangel. Dr. Ismail will serve as the managing partner, acting as CEO for the first three years of Wayak's operations. He previously served as the managing director of Intel Mobile Communications and was a senior advisor to the Egyptian Minister of Communications. Dr. Ismail holds a Ph.D. in electrical engineering from the Massachusetts Institute of Technology (MIT).

Commenting on the Joint Venture, Dr. Hend El Sherbini, Chief Executive Officer of IDH, said "Wayak falls directly in line with our strategy to diversify the Group's services and capture growth opportunities in an underserved market with strong demand for quality healthcare services. Our unique position with a vast database of some 13 million patients and a nationwide presence through our 420+ branch network will allow us to create our own clinical profiles and leverage data analytics to build targeted services. The new venture will extract favourable synergies from IDH's current business, and we expect the new services to drive additional pathology and radiology testing and create a new growing revenue base for IDH while enhancing overall patient experience."

"We are also particularly pleased to be partnering up with Dr. Ismail who brings a wealth of executive and field experience in data analytics along with a track record of start-up successes. We look forward to working with him to help Wayak capture this incredible market opportunity and contribute to the improvement of Egypt's healthcare system," El Sherbini added.

-Ends-

Contact

 
 IDH                                    [phone] 
 Sherif El-Ghamrawi,                    [phone] 
  Investor Relations Director            [e-mail] 
 
 Hudson Sandler (International Media 
  relations)                            [phone] 
 Dan de Belder                          [e-mail] 
  Bertie Berger 
 

About Integrated Diagnostics Holdings

IDH is a leading consumer healthcare company in the Middle East and Africa with operations in Egypt, Jordan, Sudan and Nigeria. The Group's core brands include Al Borg and Al Mokhtabar in Egypt, as well as Biolab (Jordan), Ultralab and Al Mokhtabar Sudan (both in Sudan) and Echo-Scan (Nigeria). A long track record for quality and safety has earned the Company a trusted reputation, as well as internationally recognised accreditations for its portfolio of over 1,400 diagnostics tests. From its base of 424 branches as of 30 June 2019, IDH will continue to add laboratories through a Hub, Spoke and Spike business model that provides a scalable platform for efficient expansion. Beyond organic growth, the Group's expansion plans include acquisitions in new Middle Eastern and African markets where its model is well-suited to capitalise on similar healthcare and consumer trends and capture a significant share of fragmented markets. IDH has been a Jersey-registered entity with a Standard Listing on the Main Market of the London Stock Exchange (ticker: IDHC) since May 2015.

IDH's forward-looking strategy rests on leveraging its established business model to achieve four key strategic goals, namely: (1) continue to expand customer reach; (2) increase the number of tests per patient; (3) expand into new geographic markets through selective, value-accretive acquisitions; and (4) introduce new medical services by leveraging the Group's network and reputable brand position. Learn more at idhcorp.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

MSCLLMBTMBJMTRL

(END) Dow Jones Newswires

September 10, 2019 02:02 ET (06:02 GMT)